Last reviewed · How we verify
Placebo in Oral Dosage Form
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials. Used for Clinical trial control arm (indication depends on the active comparator drug being studied).
At a glance
| Generic name | Placebo in Oral Dosage Form |
|---|---|
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance administered in blinded studies to establish baseline efficacy and safety profiles of investigational drugs through comparison against a non-active control. The placebo effect itself—improvement due to patient expectation and psychological factors—is well-documented but distinct from direct pharmacological action. In Phase 3 trials, placebo arms help distinguish true drug efficacy from natural disease progression and psychological benefit.
Approved indications
- Clinical trial control arm (indication depends on the active comparator drug being studied)
Common side effects
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (PHASE3)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: